Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. The company's lead product, DiaPep277 is currently in Phase III clinical trials for treating type 1 diabetes (T1D). DiaPep277 is a unique peptide representing a novel therapeutic approach to prevent the destruction of insulin producing cells in the pancreas.

Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. The company's lead product, DiaPep277 is currently in Phase III clinical trials for treating type 1 diabetes (T1D). DiaPep277 is a unique peptide repr...Show all